Satoshi Saitoh

Toranomon, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 161 publications

Serum microRNA-122 Is Associated with the Therapeutic Response to Diet and Exercise Therapy in Patients with Steatotic Liver Disease.

Serum microRNA-122 Is Associated with the Therapeutic Response to Diet and Exercise Therapy in Patients with Steatotic Liver Disease.

Journal: Internal medicine (Tokyo, Japan)

Published: May 06, 2026

When Hepatitis B Virus-Associated Glomerulonephritis Mimics Lupus Nephritis: A Case of Adult-Onset Disease With Full-House Pattern.

When Hepatitis B Virus-Associated Glomerulonephritis Mimics Lupus Nephritis: A Case of Adult-Onset Disease With Full-House Pattern.

Journal: Kidney medicine

Published: April 17, 2026

Quantitative equivalence of Quantitative Imaging Biomarkers Alliance (QIBA)-2023- and QIBA-2020-compliant MR elastography protocols for liver stiffness assessment.

Quantitative equivalence of Quantitative Imaging Biomarkers Alliance (QIBA)-2023- and QIBA-2020-compliant MR elastography protocols for liver stiffness assessment.

Journal: Abdominal radiology (New York)

Published: February 17, 2026

Correlation between protein-polydimethylsiloxane visible particle formation and computationally derived antibody surface properties.

Correlation between protein-polydimethylsiloxane visible particle formation and computationally derived antibody surface properties.

Journal: Journal of pharmaceutical sciences

Published: January 26, 2026

Serum MicroRNA-122 Predicts Early Progressive Disease in Unresectable Hepatocellular Carcinoma with Atezolizumab plus Bevacizumab Therapy.

Serum MicroRNA-122 Predicts Early Progressive Disease in Unresectable Hepatocellular Carcinoma with Atezolizumab plus Bevacizumab Therapy.

Journal: Oncology

Published: January 22, 2026

Two Cases of Hepatitis B Virus-associated Membranoproliferative Glomerulonephritis with Contrasting Renal and Survival Outcomes after Antiviral Therapy.

Two Cases of Hepatitis B Virus-associated Membranoproliferative Glomerulonephritis with Contrasting Renal and Survival Outcomes after Antiviral Therapy.

Journal: Internal medicine (Tokyo, Japan)

Published: November 12, 2025

Peripheral blood CD4+/CD8+ T cell ratio may have potential for predicting the treatment response of durvalumab plus tremelimumab therapy (STRIDE) for unresectable hepatocellular carcinoma: Preliminary report.

Peripheral blood CD4+/CD8+ T cell ratio may have potential for predicting the treatment response of durvalumab plus tremelimumab therapy (STRIDE) for unresectable hepatocellular carcinoma: Preliminary report.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: February 16, 2025

Survey and Establishment of Points to Consider for Application of Analytical Techniques to Evaluate Protein Aggregates and Insoluble Particles in Biopharmaceuticals: Experiences in Japan Biopharmaceutical Consortium.

Survey and Establishment of Points to Consider for Application of Analytical Techniques to Evaluate Protein Aggregates and Insoluble Particles in Biopharmaceuticals: Experiences in Japan Biopharmaceutical Consortium.

Journal: The AAPS journal

Published: December 26, 2024

Clinical Impact and Significant Technical Points of Transarterial Chemoembolization (TACE) Using the Smaller Drug-Eluting Bead M1 (DC Bead M1™) for Hepatocellular Carcinoma: A Case Series.

Clinical Impact and Significant Technical Points of Transarterial Chemoembolization (TACE) Using the Smaller Drug-Eluting Bead M1 (DC Bead M1™) for Hepatocellular Carcinoma: A Case Series.

Journal: Cureus

Published: November 25, 2024

An Evaluation of the Most Convenient and Effective Procedure for Reducing the Loading Time of Epirubicin Into the Drug-Eluting Bead M1 (DC Bead M1™).

An Evaluation of the Most Convenient and Effective Procedure for Reducing the Loading Time of Epirubicin Into the Drug-Eluting Bead M1 (DC Bead M1™).

Journal: Cureus

Published: October 24, 2024

Newly established borderline resectable 1 (BR1) category is one of the favorable candidates for selecting the use of multidisciplinary combination therapy in patients with advanced hepatocellular carcinoma treated with systemic therapy.

Newly established borderline resectable 1 (BR1) category is one of the favorable candidates for selecting the use of multidisciplinary combination therapy in patients with advanced hepatocellular carcinoma treated with systemic therapy.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: July 16, 2024

Long-term Favorable Efficacy of Regular and Repeated Hospitalizations with a Personalized Diet and Exercise Treatment for Steatotic Liver Disease.

Long-term Favorable Efficacy of Regular and Repeated Hospitalizations with a Personalized Diet and Exercise Treatment for Steatotic Liver Disease.

Journal: Internal medicine (Tokyo, Japan)

Published: May 08, 2024

Showing 1-12 of 161

Last Updated: 09/26/2026